Multiple antigenic sites are involved in blocking the interaction of GII.4 Norovirus Capsid with ABH Histo-Blood Group Antigens

Journal of Virology

Volumn 86, Issue 13, 2012, Pages 7414-7426

  Parra, Gabriel I ^a   Abente, Eugenio J ^a   Sandoval Jaime, Carlos ^a   Sosnovtsev, Stanislav V ^a   Bok, Karin ^a   Green, Kim Y ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ABH ANTIGEN; CAPSID PROTEIN; EPITOPE; MONOCLONAL ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NOROVIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; VIRUS ASSEMBLY; VIRUS PARTICLE; VIRUS STRAIN;

ABO BLOOD-GROUP SYSTEM; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; DISEASE OUTBREAKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENOTYPE; HUMANS; MARYLAND; MICE; MICE, INBRED BALB C; NOROVIRUS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING;

MIRIDAE; NOROVIRUS;

EID: 84860996781     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06729-11     Document Type: Article

References (69)

1. Allen DJ, Gray JJ, Gallimore CI, Xerry J, Iturriza-Gomara M. 2008. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 3:e1485. doi:10.1371/journal.pone.0001485.
2. Allen DJ, et al. 2009. Characterisation of a GII-4 norovirus variantspecific surface-exposed site involved in antibody binding. Virol. J. 6:150.
3. Almanza H, et al. 2008. Self-assembly of the recombinant capsid protein of a swine norovirus into virus-like particles and evaluation of monoclonal antibodies cross-reactive with a human strain from genogroup II. J. Clin. Microbiol. 46:3971-3979.
4. Batten CA, et al. 2006. Characterization of a cross-reactive linear epitope in human genogroup I and bovine genogroup III norovirus capsid proteins. Virology 356:179 -187.
5. Belnap DM, et al. 2003. Diversity of core antigen epitopes of hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 100:10884 -10889.
6. Bertolotti-Ciarlet A, Crawford SE, Hutson AM, Estes MK. 2003. The 3= end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J. Virol. 77:11603-11615.
7. Bok K, et al. 2009. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J. Virol. 83:11890 -11901.
8. Bok K, et al. 2011. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108: 325-330.
9. Cao S, et al. 2007. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 81:5949 -5957.
10. Choi JM, Hutson AM, Estes MK, Prasad BV. 2008. Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc. Natl. Acad. Sci. U. S. A. 105:9175-9180.
11. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. 2012. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J. Virol. 86:1214 -1226.
12. de Rougemont A, et al. 2011. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J. Virol. 85:4057- 4070.
13. El-Kamary SS, et al. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202:1649 -1658.
14. Esseili MA, Wang Q, Saif LJ. 2012. Binding of human GII.4 norovirus virus-like particles to carbohydrates of romaine lettuce leaf cell wall materials. Appl. Environ. Microbiol. 78:786 -794.
15. Fernandez-Vega V, et al. 2004. Norwalk virus N-terminal nonstructural protein is associated with disassembly of the Golgi complex in transfected cells. J. Virol. 78:4827- 4837.
16. Garcia-Barreno B, et al. 1989. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J. Virol. 63:925-932.
17. Geissler K, et al. 1999. Feline calicivirus capsid protein expression and capsid assembly in cultured feline cells. J. Virol. 73:834-838.
18. Green KY. 2007. Caliciviridae: the noroviruses, p 949-979. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
19. Green KY, et al. 2002. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. J. Infect. Dis. 185:133-146.
20. Green KY, et al. 1997. Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus. J. Clin. Microbiol. 35:1909 -1914.
21. Green KY, Lew JF, Jiang X, Kapikian AZ, Estes MK. 1993. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J. Clin. Microbiol. 31:2185- 2191.
22. Hale AD, et al. 2000. Identification of an epitope common to genogroup 1 " Norwalk-like viruses." J. Clin. Microbiol. 38:1656 -1660.
23. Hansman GS, et al. 2006. Genetic and antigenic diversity among noroviruses. J. Gen. Virol. 87:909 -919.
24. Hansman GS, et al. 2012. Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J. Virol. 86:3635-3646.
25. Hardy ME, et al. 1996. Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. Virology 217:252-261.
26. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. 2002. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76:12335-12343.
27. Herbst-Kralovetz M, Mason HS, Chen Q. 2010. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9:299 -307.
28. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression, selfassembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:6527- 6532.
29. Johnston CP, et al. 2007. Outbreak management and implications of a nosocomial norovirus outbreak. Clin. Infect. Dis. 45:534 -540.
30. Katpally U, Wobus CE, Dryden K, Virgin HW IV, Smith TJ. 2008. Structure of antibody-neutralized murine norovirus and unexpected differences from virus-like particles. J. Virol. 82:2079 -2088.
31. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495- 497.
32. Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat. Immunol. 10:573-578.
33. Leite JP, et al. 1996. Characterization of Toronto virus capsid protein expressed in baculovirus. Arch. Virol. 141:865- 875.
34. Lew JF, Kapikian AZ, Jiang X, Estes MK, Green KY. 1994. Molecular characterization and expression of the capsid protein of a Norwalk-like virus recovered from a Desert Shield troop with gastroenteritis. Virology 200:319 -325.
35. Li X, Zhou R, Tian X, Li H, Zhou Z. 2010. Characterization of a cross-reactive monoclonal antibody against norovirus genogroups I, II, III and V. Virus Res. 151:142-147.
36. Li X, et al. 2009. Identification and characterization of a native epitope common to norovirus strains GII/4, GII/7 and GII/8. Virus Res. 140:188- 193.
37. Lindesmith LC, et al. 2012. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J. Virol. 86:873- 883.
38. Lindesmith LC, Donaldson EF, Baric RS. 2010. Norovirus GII.4 strain antigenic variation. J. Virol. 85:231-242.
39. Lindesmith LC, et al. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5:e31. doi:10.1371/journal.pmed.0050031.
40. LoBue AD, et al. 2006. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24:5220 -5234.
41. + T cell epitopes. J. Virol. 84:8530-8538.
42. Lochridge VP, Hardy ME. 2007. A single-amino-acid substitution in the P2 domain of VP1 of murine norovirus is sufficient for escape from antibody neutralization. J. Virol. 81:12316 -12322.
43. Lochridge VP, Jutila KL, Graff JW, Hardy ME. 2005. Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J. Gen. Virol. 86:2799 -2806.
44. Mesquita JR, Barclay L, Nascimento MS, Vinje J. 2010. Novel norovirus in dogs with diarrhea. Emerg. Infect. Dis. 16:980 -982.
45. Oliver SL, et al. 2006. Genotype 1 and genotype 2 bovine noroviruses are antigenically distinct but share a cross-reactive epitope with human noroviruses. J. Clin. Microbiol. 44:992-998.
46. Parker TD, Kitamoto N, Tanaka T, Hutson AM, Estes MK. 2005. Identification of genogroup I and genogroup II broadly reactive epitopes on the norovirus capsid. J. Virol. 79:7402-7409.
47. Parra GI, et al. 2012. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine [Epub ahead of print.] doi:10.1016/j.vaccine.2012.03.050.
48. Patel MM, et al. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224 -1231.
49. Prasad BV, et al. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290.
50. Reeck A, et al. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J. Infect. Dis. 202:1212-1218.
51. Shiota T, et al. 2007. Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope. J. Virol. 81:12298 -12306.
52. Siebenga JJ, et al. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81:9932-9941.
53. Siebenga JJ, et al. 2009. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J. Infect. Dis. 200:802- 812.
54. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk viruslike particles in volunteers. Clin. Immunol. 108:241-247.
55. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596 -1599.
56. Tan M, et al. 2008. Noroviral P particle: structure, function and applications in virus-host interaction. Virology 382:115-123.
57. Tan M, Hegde RS, Jiang X. 2004. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J. Virol. 78:6233- 6242.
58. Tan M, et al. 2003. Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J. Virol. 77:12562-12571.
59. Thornhill TS, et al. 1977. Detection by immune electron microscopy of 26- to 27-nm viruslike particles associated with two family outbreaks of gastroenteritis. J. Infect. Dis. 135:20 -27.
60. Vinje J. 2010. A norovirus vaccine on the horizon? J. Infect. Dis. 202: 1623-1625.
61. Widdowson MA, et al. 2004. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus-United States, 2002. J. Infect. Dis. 190:27-36.
62. Wyatt LS, Moss B, Rozenblatt S. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205.
63. Wyatt RG, et al. 1974. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129:709 -714.
64. Xie QC, McCahon D, Crowther JR, Belsham GJ, McCullough KC. 1987. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J. Gen. Virol. 68:1637-1647.
65. Yoda T, et al. 2003. Precise characterization of norovirus (Norwalk-like virus)-specific monoclonal antibodies with broad reactivity. J. Clin. Microbiol. 41:2367-2371.
66. Yoda T, et al. 2001. Characterization of Norwalk virus GI specific monoclonal antibodies generated against Escherichia coli expressed capsid protein and the reactivity of two broadly reactive monoclonal antibodies generated against GII capsid towards GI recombinant fragments. BMC Microbiol. 1:24. doi:10.1186/1471-2180-1-24.
67. Yoda T, et al. 2000. Characterization of monoclonal antibodies generated against Norwalk virus GII capsid protein expressed in Escherichia coli. Microbiol. Immunol. 44:905-914.
68. Zheng DP, et al. 2006. Norovirus classification and proposed strain nomenclature. Virology 346:312-323.
69. Zheng DP, Widdowson MA, Glass RI, Vinje J. 2010. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J. Clin. Microbiol. 48:168 -177.